VESTRATA
Vestrata, a fintech company providing integrated investment solutions, has launched today. The business is led by one of the most experienced teams ever assembled by a start-up in this space and has completed a US$4 million investment round to bring its innovative proposition to the wealth management and private banking sector.
Vestrata’s proprietary technology platform is unique, and will deliver a suite of discretionary, advisory, alternatives and ESG investment solutions that help wealth managers to drive improved client engagement, control risk and reduce cost. Vestrata’s services are developed in collaboration with leading asset managers, research houses and alternatives providers, and will be delivered through an integrated, scalable and modular platform.
The Vestrata leadership team includes eight former leaders from some of the largest wealth management institutions in the world. With more than 200 years of combined experience, the team brings a deep understanding of the complexity of delivering investment solutions that match clients’ needs and preferences.
The business is led by Mark Le Lievre, Co-Founder and CEO, who was previously global Head of Products and Platforms at J.P. Morgan Private Bank and Head of Investment Content at UBS Wealth Management. The wider management team includes a number of former executives from J.P. Morgan and other global financial institutions, including:
- Doug Wurth, Chairman, formerly led the international Private Bank and Alternatives businesses at J.P. Morgan
- Kim Lennen, CTO and Co-Founder, former CTO of J.P. Morgan Private Bank (Europe)
- Lea Blinoff, Head of Solutions, former Managing Director at J.P. Morgan Private Bank
- Arun Sinha, CMO, former CMO of J.P. Morgan Private Bank
- Eric Laget, Chief Legal Officer, former in-house counsel at J.P. Morgan Asset Management
- Tim Riseborough, CFO/COO, former COO at HSBC Commercial Bank
- Sarah Newman, CCO, former Head of Investment Products at Barclays Wealth Management
Mark Le Lievre, Co-founder and CEO of Vestrata, said: “We are entering an era where wealth managers will no longer be able to rely on market appreciation to drive revenue growth. We know from first-hand experience the significant and accelerating financial and regulatory challenges faced by the wealth management industry. Firms now need to focus not only on managing their cost base but growing their revenues via enhanced client engagement.
“We understand these challenges and have built a solution to address them. If firms are to engage with clients most effectively, they need to deliver differentiated investment solutions and use a sophisticated platform to enable advisors to engage their entire book of business. I am excited about the differentiated proposition we have built and the fundamental transformation that it will enable the wealth management industry to achieve in the years ahead.”
Lea Blinoff, Head of Solutions at Vestrata, said: “Our ambition is to fuse high-quality and differentiated investment solutions with advanced technology. Vestrata integrates a variety of investment solutions, products and asset classes with powerful portfolio analytics, reporting and a robust risk management framework to ensure advisors can deliver advice specifically tailored to their clients’ needs, in a scalable and compliant way. We enable the firms we work with to deliver more ideas to more clients, leading to revenue growth, improved control and enhanced client engagement.”
ENDS
Images to accompany this story are available here .
About Vestrata
Vestrata supports wealth managers to help drive income growth by providing a modular wealth management platform and integrated investment solutions. The platform will deliver a suite of discretionary, advisory, alternatives and ESG investment solutions that support wealth managers to improve client engagement and achieve asset and revenue growth, while systematically managing investment risks and simplifying compliance. Vestrata’s modular range of services are developed in collaboration with leading providers in the market, delivered through a single, integrated and scalable platform.
Visit www.vestrata.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005736/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release
Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release
This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom